HRP20210624T1 - Režimi doziranja amisulprida za liječenje mučnine i povraćanja - Google Patents
Režimi doziranja amisulprida za liječenje mučnine i povraćanja Download PDFInfo
- Publication number
- HRP20210624T1 HRP20210624T1 HRP20210624TT HRP20210624T HRP20210624T1 HR P20210624 T1 HRP20210624 T1 HR P20210624T1 HR P20210624T T HRP20210624T T HR P20210624TT HR P20210624 T HRP20210624 T HR P20210624T HR P20210624 T1 HRP20210624 T1 HR P20210624T1
- Authority
- HR
- Croatia
- Prior art keywords
- amisulpride
- antiemetic
- phase
- injectable
- kit
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1506116.1A GB201506116D0 (en) | 2015-04-10 | 2015-04-10 | Kit and combination therapy for nausea and vomiting |
| EP16716659.4A EP3280392B1 (en) | 2015-04-10 | 2016-04-11 | Dosage regimens of amisulpride for treating nausea and vomiting |
| PCT/GB2016/050998 WO2016162695A1 (en) | 2015-04-10 | 2016-04-11 | Combinations of amisulpride and another anti-emetic for treating nausea and vomiting |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210624T1 true HRP20210624T1 (hr) | 2021-05-28 |
Family
ID=53333601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210624TT HRP20210624T1 (hr) | 2015-04-10 | 2016-04-11 | Režimi doziranja amisulprida za liječenje mučnine i povraćanja |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US10322106B2 (https=) |
| EP (1) | EP3280392B1 (https=) |
| JP (1) | JP6812360B2 (https=) |
| KR (2) | KR20240125705A (https=) |
| CN (1) | CN107872975A (https=) |
| AU (1) | AU2016246104B2 (https=) |
| CA (1) | CA2982251C (https=) |
| CY (1) | CY1124184T1 (https=) |
| DK (1) | DK3280392T3 (https=) |
| ES (1) | ES2866933T3 (https=) |
| GB (1) | GB201506116D0 (https=) |
| HR (1) | HRP20210624T1 (https=) |
| HU (1) | HUE054165T2 (https=) |
| IL (2) | IL295650A (https=) |
| LT (1) | LT3280392T (https=) |
| MX (1) | MX388735B (https=) |
| PL (1) | PL3280392T3 (https=) |
| PT (1) | PT3280392T (https=) |
| RS (1) | RS61760B1 (https=) |
| SI (1) | SI3280392T1 (https=) |
| SM (1) | SMT202100216T1 (https=) |
| WO (1) | WO2016162695A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201618425D0 (en) * | 2016-11-01 | 2016-12-14 | Acacia Pharma Ltd | method |
| GB201702250D0 (en) | 2017-02-10 | 2017-03-29 | Acacia Pharma Ltd | Method |
| CA3084953A1 (en) | 2017-12-05 | 2019-06-13 | Sunovion Pharmaceuticals Inc. | Nonracemic mixtures and uses thereof |
| AU2018378348B2 (en) | 2017-12-05 | 2024-09-19 | Sunovion Pharmaceuticals Inc. | Crystal forms and production methods thereof |
| AU2020286441A1 (en) | 2019-06-04 | 2022-01-06 | Sunovion Pharmaceuticals Inc. | Modified release formulations and uses thereof |
| WO2023179542A1 (en) | 2022-03-21 | 2023-09-28 | Gasherbrum Bio , Inc. | 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes |
| WO2023198140A1 (en) | 2022-04-14 | 2023-10-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| JP2026501171A (ja) | 2022-12-15 | 2026-01-14 | ガシャーブラム・バイオ・インコーポレイテッド | Ｇｌｐ－１アゴニスト活性を有する化合物の塩および固体形態 |
| JP2026501285A (ja) | 2022-12-22 | 2026-01-14 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環式ｇｌｐ－１アゴニスト |
| CN120693338A (zh) | 2022-12-22 | 2025-09-23 | 加舒布鲁姆生物公司 | 杂环的glp-1激动剂 |
| AU2024222719A1 (en) | 2023-02-16 | 2025-08-21 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| US20250019389A1 (en) | 2023-06-30 | 2025-01-16 | Gasherbrum Bio, Inc. | Heterocyclic agonists |
| WO2025015269A1 (en) | 2023-07-13 | 2025-01-16 | Aconcagua Bio, Inc. | Compounds, compositions, and methods |
| WO2025015268A1 (en) | 2023-07-13 | 2025-01-16 | Aconcagua Bio, Inc. | Modulators of calcitonin receptor and/or amylin receptor activity |
| WO2025045208A1 (en) | 2023-08-31 | 2025-03-06 | Gasherbrum Bio, Inc. | Heteroaryl-heterocycloalkyl-based glp-1 agonists |
| WO2025137307A1 (en) | 2023-12-20 | 2025-06-26 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| WO2025171341A2 (en) | 2024-02-08 | 2025-08-14 | Aconcagua Bio, Inc. | Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity |
| WO2025171340A1 (en) | 2024-02-08 | 2025-08-14 | Aconcagua Bio, Inc. | The treatment of calcitonin- and/or amylin-receptor associated conditions |
| WO2025189141A1 (en) | 2024-03-08 | 2025-09-12 | Annapurna Bio, Inc. | Methods for treating obesity and increasing weight loss |
| WO2026041075A1 (en) | 2024-08-21 | 2026-02-26 | Gasherbrum Bio, Inc. | Gpl-1 agonists |
| WO2026051998A1 (en) | 2024-09-04 | 2026-03-12 | Aconcagua Bio, Inc. | Compounds, compositions, and methods |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201003962D0 (en) | 2010-03-10 | 2010-04-21 | Tangentix Ltd | Multimedia content delivery system |
| GB201004020D0 (en) * | 2010-03-11 | 2010-04-21 | Acacia Pharma Ltd | New therapeutic use |
| US20150018360A1 (en) * | 2011-09-13 | 2015-01-15 | Biomed Valley Discoveries, Inc. | Compositions and methods for treating metabolic disorders |
-
2015
- 2015-04-10 GB GBGB1506116.1A patent/GB201506116D0/en not_active Ceased
-
2016
- 2016-04-11 CN CN201680030994.9A patent/CN107872975A/zh active Pending
- 2016-04-11 LT LTEP16716659.4T patent/LT3280392T/lt unknown
- 2016-04-11 KR KR1020247026775A patent/KR20240125705A/ko active Pending
- 2016-04-11 MX MX2017012991A patent/MX388735B/es unknown
- 2016-04-11 HU HUE16716659A patent/HUE054165T2/hu unknown
- 2016-04-11 AU AU2016246104A patent/AU2016246104B2/en active Active
- 2016-04-11 EP EP16716659.4A patent/EP3280392B1/en active Active
- 2016-04-11 IL IL295650A patent/IL295650A/en unknown
- 2016-04-11 KR KR1020177032393A patent/KR102711661B1/ko active Active
- 2016-04-11 CA CA2982251A patent/CA2982251C/en active Active
- 2016-04-11 SM SM20210216T patent/SMT202100216T1/it unknown
- 2016-04-11 SI SI201631183T patent/SI3280392T1/sl unknown
- 2016-04-11 ES ES16716659T patent/ES2866933T3/es active Active
- 2016-04-11 JP JP2017553076A patent/JP6812360B2/ja active Active
- 2016-04-11 DK DK16716659.4T patent/DK3280392T3/da active
- 2016-04-11 US US15/565,479 patent/US10322106B2/en active Active
- 2016-04-11 PT PT167166594T patent/PT3280392T/pt unknown
- 2016-04-11 WO PCT/GB2016/050998 patent/WO2016162695A1/en not_active Ceased
- 2016-04-11 PL PL16716659T patent/PL3280392T3/pl unknown
- 2016-04-11 RS RS20210407A patent/RS61760B1/sr unknown
- 2016-04-11 HR HRP20210624TT patent/HRP20210624T1/hr unknown
-
2017
- 2017-10-08 IL IL254929A patent/IL254929A0/en unknown
-
2021
- 2021-05-20 CY CY20211100442T patent/CY1124184T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016246104B2 (en) | 2018-12-13 |
| IL295650A (en) | 2022-10-01 |
| AU2016246104A1 (en) | 2017-11-30 |
| HUE054165T2 (hu) | 2021-08-30 |
| CA2982251A1 (en) | 2016-10-13 |
| KR102711661B1 (ko) | 2024-10-02 |
| KR20180016350A (ko) | 2018-02-14 |
| CY1124184T1 (el) | 2022-07-22 |
| PL3280392T3 (pl) | 2021-10-18 |
| US10322106B2 (en) | 2019-06-18 |
| EP3280392B1 (en) | 2021-02-24 |
| WO2016162695A1 (en) | 2016-10-13 |
| PT3280392T (pt) | 2021-03-12 |
| HK1250913A1 (en) | 2019-01-18 |
| US20180071249A1 (en) | 2018-03-15 |
| EP3280392A1 (en) | 2018-02-14 |
| SI3280392T1 (sl) | 2021-08-31 |
| JP2018510898A (ja) | 2018-04-19 |
| LT3280392T (lt) | 2021-04-26 |
| CA2982251C (en) | 2023-06-13 |
| IL254929A0 (en) | 2017-12-31 |
| CN107872975A (zh) | 2018-04-03 |
| DK3280392T3 (da) | 2021-03-08 |
| RS61760B1 (sr) | 2021-05-31 |
| GB201506116D0 (en) | 2015-05-27 |
| MX2017012991A (es) | 2018-02-01 |
| MX388735B (es) | 2025-03-20 |
| ES2866933T3 (es) | 2021-10-20 |
| KR20240125705A (ko) | 2024-08-19 |
| SMT202100216T1 (it) | 2021-05-07 |
| JP6812360B2 (ja) | 2021-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210624T1 (hr) | Režimi doziranja amisulprida za liječenje mučnine i povraćanja | |
| JP2018510898A5 (https=) | ||
| NZ725006A (en) | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns | |
| EP4279135A3 (en) | Use of a vegf antagonist to treat diabetic retinopathy | |
| JP2012180381A5 (https=) | ||
| HRP20251088T1 (hr) | Upotreba dugodjelujućih peptida glp‑1 | |
| MX2021013139A (es) | Composicion farmaceutica para la prevencion y/o tratamiento de dermatitis atopica que comprende antagonista de interleucina 31 (il-31) como ingrediente activo. | |
| HRP20201027T1 (hr) | Režim doziranja za propuštene doze injektibilnih estera paliperidona s produljenim djelovanjem | |
| HRP20230300T1 (hr) | Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije | |
| MX387113B (es) | Composiciones acuosas de capsaicinoides que comprenden un analgésico y un vehículo acuoso, y uso de las mismas para el tratamiento del dolor. | |
| MX2018005715A (es) | Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash. | |
| HRP20201632T1 (hr) | Režimi doziranja melflufena kod raka | |
| CO2021007186A2 (es) | Composición farmacéutica para el tratamiento de la hipertensión arterial pulmonar | |
| MY173582A (en) | Extended-release formulation for reducing the frequency of urination and method of use thereof | |
| WO2012145575A3 (en) | Therapy for leukemia | |
| MX2018000084A (es) | Una composicion farmaceutica que comprende amlodipino, valsartan y rosuvastatina. | |
| FI3709996T3 (fi) | Kumariinijohdannainen soluproliferaation häiriön hoitamiseksi tai ennaltaehkäisemiseksi | |
| HRP20230894T1 (hr) | Režimi i postupci liječenja multiple skleroze ofatumumabom | |
| HK1243704A1 (zh) | 用於在未接触疟疾的受试者中预防疟疾的他非诺喹的新方案 | |
| MX2022005628A (es) | Regimen de dosificacion para agentes anti-bcma. | |
| CO2021011046A2 (es) | Composición farmacéutica que comprende macitentán para el tratamiento de la hipertensión pulmonar tromboembólica crónica | |
| HRP20180316T1 (hr) | Izolirani čvrsti oblik anamorelin monohidroklorida s niskim molarnim odnosom klorida: anamolerina i niskim sadržajem rezidualnog organskog otapala | |
| HRP20171708T1 (hr) | FARMACEUTSKI PRIPRAVAK KOJI SADRŽI (1R,4R)-6'-FLUORO-N,N-DIMETIL-4-FENIL-4',9'-DIHIDRO-3'H-SPIRO[CIKLOHEKSAN-1,1'-PIRANO [3,4,b]INDOL]-4-AMIN I GABAPENTINOID | |
| SI2686002T1 (en) | A method for reducing influenza-like symptoms associated with intramuscular delivery of interferon by the rapid titration-enhancing regimen | |
| CO2018013792A2 (es) | Regímenes de dosificación de vortioxetina para el rápido inicio del efecto antidepresivo |